 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...63646566676869707172737475» |
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: TRIASTIN: Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema (clinicaltrials.gov) - May 30, 2013
P4, N=60, Recruiting, Sponsor: Medical University of Vienna
N=30 --> 60
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Liberty: Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - May 23, 2013
P4, N=60, Recruiting, Sponsor: Retinal Consultants of Arizona
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Combination therapy: Revolution: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study (clinicaltrials.gov) - May 19, 2013
P2, N=20, Active, not recruiting, Sponsor: Retina Associates of Florida, P.A.
N=30 --> 60 Recruiting --> Active, not recruiting
- ||||| Beovu (brolucizumab-dbll) / Novartis
New P2 trial: ESBA1008 Microvolume Study (clinicaltrials.gov) - May 6, 2013
P2, N=52, Recruiting, Sponsor: Alcon Research
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Effect of Ranibizumab on Malignant Conjunctival Neoplasia (clinicaltrials.gov) - May 2, 2013
P1, N=5, Completed, Sponsor: The New York Eye Cancer Center
Recruiting --> Active, not recruiting N=10 --> 5
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Effect of Ranibizumab on Malignant Conjunctival Neoplasia (clinicaltrials.gov) - May 2, 2013
P1, N=5, Completed, Sponsor: The New York Eye Cancer Center
N=10 --> 5 Active, not recruiting --> Completed
- ||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Enrollment change: Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - May 1, 2013
P2, N=363, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed N=300 --> 363
- ||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
New P4 trial, Combination therapy, Monotherapy: EVEREST II: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (clinicaltrials.gov) - May 1, 2013
P4, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema (clinicaltrials.gov) - May 1, 2013
P3, N=187, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (clinicaltrials.gov) - May 1, 2013
P1/2, N=30, Recruiting, Sponsor: Southeast Retina Center, Georgia
- ||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Enrollment closed: Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - May 1, 2013
P2, N=363, Active, not recruiting, Sponsor: Allergan
N=300 --> 363 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: Ranibizumab as a Rescue Therapy for Diabetic Macular Edema (clinicaltrials.gov) - Apr 30, 2013
P2, N=0, Withdrawn, Sponsor: New England Retina Associates
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab as a Rescue Therapy for Diabetic Macular Edema (clinicaltrials.gov) - Apr 30, 2013
P2, N=0, Withdrawn, Sponsor: New England Retina Associates
Not yet recruiting --> Withdrawn N=30 --> 0
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) (clinicaltrials.gov) - Apr 30, 2013
P2, N=10, Completed, Sponsor: New England Retina Associates
N=30 --> 0 Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma (clinicaltrials.gov) - Apr 30, 2013
P3, N=10, Completed, Sponsor: New England Retina Associates
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. (clinicaltrials.gov) - Apr 23, 2013
P3, N=187, Recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes (clinicaltrials.gov) - Apr 22, 2013
P=N/A, N=70, Recruiting, Sponsor: McMaster University
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Jan 2012
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes (clinicaltrials.gov) - Apr 22, 2013
P=N/A, N=70, Recruiting, Sponsor: McMaster University
Initiation date: Jul 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: RACE: Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Apr 18, 2013
P2, N=99, Completed, Sponsor: Alcon Research
Not yet recruiting --> Recruiting N=49 --> 99
- ||| Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients (clinicaltrials.gov) - Apr 17, 2013
P1/2, N=376, Completed, Sponsor: Alcon Research
N=49 --> 99 N=90 --> 376
- |||| Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients (clinicaltrials.gov) - Apr 17, 2013
P1/2, N=376, Completed, Sponsor: Alcon Research
N=90 --> 376 Recruiting --> Completed
- || Lucentis (ranibizumab) / Roche, Novartis, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2/3 trial: TAPAS: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (clinicaltrials.gov) - Apr 16, 2013
P2/3, N=55, Recruiting, Sponsor: King's College Hospital NHS Trust
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: RESPOND: Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) (clinicaltrials.gov) - Apr 15, 2013
P3, N=242, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: RABIMO: Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. (clinicaltrials.gov) - Apr 11, 2013
P4, N=40, Completed, Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: ORION: Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (clinicaltrials.gov) - Apr 8, 2013
P4, N=45, Recruiting, Sponsor: Valley Retina Institute
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion (clinicaltrials.gov) - Apr 7, 2013
P4, N=202, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy (clinicaltrials.gov) - Apr 4, 2013
P1/2, N=34, Completed, Sponsor: Jang Won Heo
Active, not recruiting --> Completed N=26 --> 34
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy (clinicaltrials.gov) - Apr 4, 2013
P1/2, N=34, Completed, Sponsor: Jang Won Heo
N=26 --> 34 Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage (clinicaltrials.gov) - Apr 2, 2013
P4, N=20, Recruiting, Sponsor: Hospital Regional de S
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment (clinicaltrials.gov) - Apr 2, 2013
P2, N=0, Recruiting, Sponsor: Poitiers University Hospital
- |||| Votrient (pazopanib) / Novartis, BeiGene, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 20, 2013
P2, N=510, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: DRAGON: Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (clinicaltrials.gov) - Mar 17, 2013
P4, N=310, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 17, 2013
P2/3, N=45, Completed, Sponsor: Retina Macula Institute
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab (clinicaltrials.gov) - Mar 11, 2013
P4, N=49, Completed, Sponsor: Pusan National University Hospital
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: RVOFV: Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision (clinicaltrials.gov) - Feb 18, 2013
P4, N=40, Recruiting, Sponsor: Seoul National University Bundang Hospital
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: RaDiVit: Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study (clinicaltrials.gov) - Feb 18, 2013
P4, N=30, Active, not recruiting, Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LUCIDATE: Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation (clinicaltrials.gov) - Feb 18, 2013
P4, N=37, Completed, Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Injections into the eye (drug Lucentis) in diabetic patients in whom no further treatment is currently available in clinic when they have developed swelling of the centre of the macula associated with lack of blood supply. (EUDRACT) - Feb 14, 2013
P3, N=80, Ongoing, Sponsor: Moorfields Eye Hospital
- ||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: EVERGREEN: Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=196, Completed, Sponsor: Sequenom, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Monotherapy: Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion (clinicaltrials.gov) - Feb 6, 2013
P3, N=47, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=31 --> 47
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Surgery: VITARM: Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone (clinicaltrials.gov) - Feb 6, 2013
P2, N=70, Active, not recruiting, Sponsor: Attila Vajas
N=31 --> 47 Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion (clinicaltrials.gov) - Feb 6, 2013
P3, N=47, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: GEFAL: French Evaluation Group Avastin Versus Lucentis (clinicaltrials.gov) - Feb 5, 2013
P3, N=501, Completed, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: OCTAVE: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 29, 2013
P3, N=670, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: DRAGON: Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (clinicaltrials.gov) - Jan 22, 2013
P4, N=310, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: SEAGUL2: Study EvAluating Genotypes While Using Lucentis 2 (clinicaltrials.gov) - Jan 21, 2013
P4, N=66, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema (clinicaltrials.gov) - Jan 17, 2013
P2, N=71, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments (clinicaltrials.gov) - Jan 16, 2013
P4, N=20, Active, not recruiting, Sponsor: University Hospital, Bonn
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=2609, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting N=3591 --> 2609
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: LucERG: Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: University of Luebeck
N=3591 --> 2609 Recruiting --> Active, not recruiting